CAPRCapricor Therapeutics, Inc.

CAPR Stock Price, Valuation & Chart | Capricor Therapeutics, Inc.

Compare

$9.890-0.12 (-1.20%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology CAPR intrinsic value CAPR calculated fair value vs price

Overview Financials Dividends Ratios

CAPR Historical price chart

CAPR Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization568.78M

PE Ratio-4.04

EPS-2.45

Trading Volume5.12M

Today's High/Low10.65/9.6

Dividend Yield0.00

52 Week High/Low40.37/2.96

Shares Outstanding57.51M

CAPR Financial Statement

CAPR Analyst ratings

CAPR Analysis & performance metrics

CAPR Company profile

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and…

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage…

CAPR Management team

Name

Position

Frank Isaac Litvack FACC, M.D.

Executive Chairman of the Board

Karen G. Krasney Esq., J.D.

Executive Vice President, General Counsel & Secretary

Linda Marbán Ph.D.CEO

Co-Founder, President, Chief Executive Officer & Director

Anthony J. Bergmann M.B.A.CFO

Chief Financial Officer & Corporate Treasurer

Kristi A. H. Elliott Ph.D.

Chief Science Officer

Mark Awadalla

Chief Development Officer

Catherine Lee Kelleher

Consultant

Minghao Sun Ph.D.

Senior Vice President of Research & Product Development

Name

Position

Frank Isaac Litvack FACC, M.D.

Executive Chairman of the Board

Karen G. Krasney Esq., J.D.

Executive Vice President, General Counsel & Secretary

Linda Marbán Ph.D.CEO

Co-Founder, President, Chief Executive Officer & Director

Anthony J. Bergmann M.B.A.CFO

Chief Financial Officer & Corporate Treasurer

Kristi A. H. Elliott Ph.D.

Chief Science Officer

Mark Awadalla

Chief Development Officer

Catherine Lee Kelleher

Consultant

Minghao Sun Ph.D.

Senior Vice President of Research & Product Development

Management Team

Frank Isaac Litvack FACC, M.D.

Executive Chairman of the Board

Karen G. Krasney Esq., J.D.

Executive Vice President, General Counsel & Secretary

Linda Marbán Ph.D.CEO

Co-Founder, President, Chief Executive Officer & Director

Anthony J. Bergmann M.B.A.CFO

Chief Financial Officer & Corporate Treasurer

Kristi A. H. Elliott Ph.D.

Chief Science Officer

Mark Awadalla

Chief Development Officer

Catherine Lee Kelleher

Consultant

Minghao Sun Ph.D.

Senior Vice President of Research & Product Development

Management

Frank Isaac Litvack FACC, M.D.

Executive Chairman of the Board

Karen G. Krasney Esq., J.D.

Executive Vice President, General Counsel & Secretary

Linda Marbán Ph.D.CEO

Co-Founder, President, Chief Executive Officer & Director

Anthony J. Bergmann M.B.A.CFO

Chief Financial Officer & Corporate Treasurer

Kristi A. H. Elliott Ph.D.

Chief Science Officer

Mark Awadalla

Chief Development Officer

Catherine Lee Kelleher

Consultant

Minghao Sun Ph.D.

Senior Vice President of Research & Product Development

Total 8 executives

CAPR Frequently asked questions

What is Capricor Therapeutics, Inc. (CAPR) Stock Price?

Current stock price of Capricor Therapeutics, Inc. (CAPR) stock is $9.890. The stock price is -1.20% lower in the session. The intraday range can be seen from this page. Volume of Capricor Therapeutics, Inc. (CAPR) stock is 5.12M.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Capricor Therapeutics, Inc. (CAPR) stock price going up or down today?

The stock price of Capricor Therapeutics, Inc. (CAPR) can change with earnings, company news, and overall market sentiment. Capricor Therapeutics, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Capricor Therapeutics, Inc. stock expensive at its current price?

Whether Capricor Therapeutics, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for CAPR on this page is -4.04. EPS on this page is -2.45. Compare those figures with peers and growth expectations before deciding if the current Capricor Therapeutics, Inc. price is justified.

How has the stock price of Capricor Therapeutics, Inc. (CAPR) performed historically?

Historical performance for Capricor Therapeutics, Inc. (CAPR) is shown on the price chart on this page. Review multi-period moves alongside volume to see how CAPR reacted to past earnings and market events.

Should I buy Capricor Therapeutics, Inc. (CAPR) stock, at this price?

Buying Capricor Therapeutics, Inc. (CAPR) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.